An orally administered PCSK9 has always been a race.
https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018
Merck has put this through a phase 1 AND now a phase 2 while NYR have been pissing about, still preclinical.
They had a 1-2 year window and it is likely they have blown it.
I don't have much skin in this game, it's really just a bit of fun now. I'm fine holding to see how it plays out. There is still a slim chance of a payout.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.030(11.5%) |
Mkt cap ! $48.51M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 23.0¢ | $94.96K | 395.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6409 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 11.51am 19/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |